CytomX Therapeutics, Inc. cash flow to debt ratio of -1.78K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

CytomX Therapeutics, Inc.'s free cash flow has increased -12.40% from $-86.54M last year to $-75.81M, signaling increasing performance

CytomX Therapeutics, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

CytomX Therapeutics, Inc.'s debt has increased relative to shareholder equity from -20.58 last year to 0.02 today, signaling weakened financials

CytomX Therapeutics, Inc. has a net cash position, so leverage is healthy.

CytomX Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

CytomX Therapeutics, Inc.'s profit margin has decreased (1.99K%) in the last year from 23.08% to -435.21%, signaling decreasing performance

CytomX Therapeutics, Inc.'s short-term assets of $143.92M exceed its short-term liabilities of $46.62M

CytomX Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

CytomX Therapeutics, Inc.'s return on equity of -38.46%, is lower than 15.00%, indicating bad performance

CytomX Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

CytomX Therapeutics, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

CytomX Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

CytomX Therapeutics, Inc. has negative free cash flow, indicating cash burn

CytomX Therapeutics, Inc.'s yearly earnings has decreased 154.50% since last year from $31.87M to $-17.37M, signaling decreasing performance

CytomX Therapeutics, Inc.'s yearly revenue has decreased 44.82% since last year from $138.10M to $76.20M, signaling decreasing performance

ROIC -25.42% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

CytomX Therapeutics, Inc.'s 3-year revenue CAGR of 12.75% is positive, indicating growing revenue over the past 3 years

CytomX Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

CytomX Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

CytomX Therapeutics, Inc. has insufficient data to evaluate this check.

CytomX Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CytomX Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

CytomX Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

CytomX Therapeutics, Inc. is overvalued relative to its fair value price of -1.65 based on Earnings Fair Value model

CytomX Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CytomX Therapeutics, Inc. has a price-to-book ratio of 2.49x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

CytomX Therapeutics, Inc. has a price-to-sales ratio of 41.15x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue